PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2021.10072021362312-321Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint InhibitorsShintaro Iwama, Tomoko Kobayashi, Hiroshi Arimahttp://e-enm.org/upload/pdf/enm-2021-1007.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.1007, http://e-enm.org/upload/pdf/enm-2021-1007.pdf
Cancer10.1002/cncr.31200201812461111-1121Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical managementRomualdo Barroso-Sousa, Patrick A. Ott, F. Stephen Hodi, Ursula B. Kaiser, Sara M. Tolaney, Le Minhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.31200, https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.31200
Endocrine Emergencies10.1016/b978-0-323-76097-3.00024-72022301-314Endocrinopathies Associated With Immune Checkpoint InhibitorsMonica Girotrahttps://api.elsevier.com/content/article/PII:B9780323760973000247?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323760973000247?httpAccept=text/plain
Cancer Cytopathology10.1002/cncy.219512017126111-19Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathologyDouglas P. Clarkhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncy.21951, http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncy.21951/fullpdf
Immune Network10.4110/in.2020.20.e92020201Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint InhibitorsJuwhan Choi, Sung Yong Leehttps://synapse.koreamed.org/pdf/10.4110/in.2020.20.e9, https://synapse.koreamed.org/DOIx.php?id=10.4110/in.2020.20.e9, https://immunenetwork.org/DOIx.php?id=10.4110/in.2020.20.e9
Annals of Oncology10.1016/j.annonc.2021.05.440202132S255SY10-4 Clinical biomarkers to predict the efficacy of immune checkpoint inhibitorsSatoru Miurahttps://api.elsevier.com/content/article/PII:S0923753421016409?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753421016409?httpAccept=text/plain
Clinical and Translational Oncology10.1007/s12094-021-02579-920212391782-1793Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)J. Liu, Q. Wu, S. Wu, X. Xiehttps://link.springer.com/content/pdf/10.1007/s12094-021-02579-9.pdf, https://link.springer.com/article/10.1007/s12094-021-02579-9/fulltext.html, https://link.springer.com/content/pdf/10.1007/s12094-021-02579-9.pdf
Clinical Neurophysiology10.1016/j.clinph.2018.02.05420181295e27-e28S12-4. Myasthenia gravis induced by immune checkpoint inhibitorsShigeaki Suzukihttps://api.elsevier.com/content/article/PII:S1388245718301548?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1388245718301548?httpAccept=text/plain
Clinical Endocrinology10.1111/cen.130632016853331-339Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical reviewM.N Joshi, B.C. Whitelaw, M.T.P. Palomar, Y. Wu, P.V. Carrollhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fcen.13063
ESMO Open10.1136/esmoopen-2020-000791202054e000791Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancerByung Woog Kang, Ian Chauhttps://api.elsevier.com/content/article/PII:S2059702920326521?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2059702920326521?httpAccept=text/plain, https://syndication.highwire.org/content/doi/10.1136/esmoopen-2020-000791